ILUMYA 100 mg/mL
tildrakizumab-asmn · INJECTION, SOLUTION · Sun Pharmaceutical Industries, Inc.
ILUMYA is a injection, solution containing tildrakizumab-asmn at 100 mg/mL, taken subcutaneous. Manufactured by Sun Pharmaceutical Industries, Inc..
Key Facts
- Brand Name
- ILUMYA
- Generic Name
- tildrakizumab-asmn
- NDC Code (Product)
47335-177- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Strength
- 100 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761067
- Drug Class
- Interleukin-23 Antagonist [EPC]
- Marketing Start
- 08/06/2018
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is ILUMYA used for?
ILUMYA contains tildrakizumab-asmn. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is ILUMYA a controlled substance?
ILUMYA is not classified as a controlled substance by the DEA.
What is the generic name for ILUMYA?
The generic name for ILUMYA is tildrakizumab-asmn. There are no other listed brand versions of tildrakizumab-asmn.
What is the NDC code for ILUMYA 100 mg/mL?
The NDC (National Drug Code) for ILUMYA 100 mg/mL is 47335-177, listed by Sun Pharmaceutical Industries, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)